Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent anaplastic astrocytoma and glioblastoma in adults.

被引：5
|
作者：
Wu, Jing
Yuan, Ying
Cordova, Christine
Aboud, Orwa
Penas-Prado, Marta
Theeler, Brett James
Bryla, Christine
Su, Yu-Ting
Grajkowska, Ewa
McCoy, Ann
Boris, Lisa
Siegel, Christine
Antony, Ramya
Garren, Nancy
Lawhon, Tracy
Armstrong, Terri
Gilbert, Mark R.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] NIH, Bldg 10, Bethesda, MD 20892 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA
[4] Walter Reed Natl Mil Med Ctr, Gaithersburg, MD USA
[5] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA
[6] NCI, Bethesda, MD 20892 USA
[7] Leidos Biomed Res Inc, Frederick, MD USA
[8] Adastra Pharmaceut Inc, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.2031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2031
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study
    Chheda, Milan G.
    Wen, Patrick Y.
    Hochberg, Fred H.
    Chi, Andrew S.
    Drappatz, Jan
    Eichler, April F.
    Yang, Daniel
    Beroukhim, Rameen
    Norden, Andrew D.
    Gerstner, Elizabeth R.
    Betensky, Rebecca A.
    Batchelor, Tracy T.
    JOURNAL OF NEURO-ONCOLOGY, 2015, 121 (03) : 627 - 634
  • [32] Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study
    Milan G. Chheda
    Patrick Y. Wen
    Fred H. Hochberg
    Andrew S. Chi
    Jan Drappatz
    April F. Eichler
    Daniel Yang
    Rameen Beroukhim
    Andrew D. Norden
    Elizabeth R. Gerstner
    Rebecca A. Betensky
    Tracy T. Batchelor
    Journal of Neuro-Oncology, 2015, 121 : 627 - 634
  • [33] Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma BrUOG329, A Phase I Brown University Oncology Research Group Trial
    Elinzano, Heinrich
    Toms, Steven
    Robison, Jordan
    Mohler, Alex
    Carcieri, Arieana
    Cielo, Deus
    Donnelly, Jennifer
    Disano, Dylan
    Vatketich, John
    Baekey, John
    Sturtevant, Ashlee
    MacKinnon, Kelsey
    Wood, Roxanne
    Safran, Howard
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (02): : 49 - 52
  • [34] A randomized phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose-dense compared to metronomic TMZ and maintenance cis-retinoic acid for patients with newly diagnosed glioblastoma multiforme (GBM)
    Clarke, Jennifer
    Sul, Joohee
    DeAngelis, Lisa
    Lassman, Andrew
    Hormigo, Adilia
    Nolan, Craig
    Gavrilovic, Igor
    Gu, Bin
    Panageas, Kathy
    Abrey, Lauren
    NEURO-ONCOLOGY, 2007, 9 (04) : 530 - 530
  • [35] RTOG 0525: A RANDOMIZED PHASE III TRIAL COMPARING STANDARD ADJUVANT TEMOZOLOMIDE (TMZ) WITH A DOSE-DENSE (DD) SCHEDULE IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Gilbert, Mark R.
    Wang, Meihua
    Aldape, Ken D.
    Stupp, Roger
    Hegi, Monika
    Jaeckle, Kurt A.
    Armstrong, Terri S.
    Wefel, Jeffrey S.
    Won, Minhee
    Blumenthal, Deborah T.
    Mahajan, Anita
    Schultz, Christopher J.
    Erridge, Sara C.
    Brown, Paul D.
    Chakravarti, Arnab
    Curran, Walter J., Jr.
    Mehta, Minesh P.
    NEURO-ONCOLOGY, 2011, 13 : 51 - 51
  • [36] RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM).
    Gilbert, M. R.
    Wang, M.
    Aldape, K. D.
    Stupp, R.
    Hegi, M.
    Jaeckle, K. A.
    Armstrong, T. S.
    Wefel, J. S.
    Won, M.
    Blumenthal, D. T.
    Mahajan, A.
    Schultz, C. J.
    Erridge, S. C.
    Brown, P. D.
    Chakravarti, A.
    Curran, W. J.
    Mehta, M. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma
    Gilbert, Mark R.
    Gonzalez, Javier
    Hunter, Kathy
    Hess, Kenneth
    Giglio, Pierre
    Chang, Eric
    Puduvalli, Vinay
    Groves, Morris D.
    Colman, Howard
    Conrad, Charles
    Levin, Victor
    Woo, Shaio
    Mahajan, Anita
    de Groot, John
    Yung, W. K. Alfred
    NEURO-ONCOLOGY, 2010, 12 (11) : 1167 - 1172
  • [38] Phase I lead-in to a 2x2x2 factorial trial of dose-dense temozolomide, memantine, mefloquine, and metformin as postradiation adjuvant therapy of glioblastoma (GBM).
    Penas-Prado, Marta
    Groves, Morris D.
    Mammoser, Aaron A.
    Melguizo, Isaac
    De Groot, John Frederick
    Conrad, Charles A.
    Tremont-Lukats, Ivo
    Loghin, Monica Elena
    Puduvalli, Vinay K.
    Sulman, Erik P.
    Hess, Kenneth R.
    Aldape, Kenneth D.
    Gilbert, Mark R.
    Yung, W. K. Alfred
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
    Weathers, Shiao-Pei S.
    Han, Stan Xiaosi
    Liu, Diane D.
    Conrad, Charles A.
    Gilbert, Mark R.
    Loghin, Monica Elena
    O'Brien, Barbara Jane
    Penas-Prado, Marta
    Puduvalli, Vinay K.
    Tremont-Lukats, Ivo
    Yung, W. K. Alfred
    De Groot, John Frederick
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
    Shiao-Pei Weathers
    Xiaosi Han
    Diane D. Liu
    Charles A. Conrad
    Mark R. Gilbert
    Monica E. Loghin
    Barbara J. O’Brien
    Marta Penas-Prado
    Vinay K. Puduvalli
    Ivo Tremont-Lukats
    Rivka R. Colen
    W. K. Alfred Yung
    John F. de Groot
    Journal of Neuro-Oncology, 2016, 129 : 487 - 494
12345